CN105283171A - 包含生物活性物的内聚性液体食团 - Google Patents
包含生物活性物的内聚性液体食团 Download PDFInfo
- Publication number
- CN105283171A CN105283171A CN201480032861.6A CN201480032861A CN105283171A CN 105283171 A CN105283171 A CN 105283171A CN 201480032861 A CN201480032861 A CN 201480032861A CN 105283171 A CN105283171 A CN 105283171A
- Authority
- CN
- China
- Prior art keywords
- food
- mucus
- compound
- food group
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 39
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 114
- 150000001875 compounds Chemical class 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000007864 aqueous solution Substances 0.000 claims abstract description 24
- 230000009747 swallowing Effects 0.000 claims abstract description 17
- 230000001737 promoting effect Effects 0.000 claims abstract description 6
- 210000003097 mucus Anatomy 0.000 claims description 70
- 208000019505 Deglutition disease Diseases 0.000 claims description 48
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 40
- 241000196324 Embryophyta Species 0.000 claims description 31
- 239000000084 colloidal system Substances 0.000 claims description 28
- 229920000642 polymer Polymers 0.000 claims description 28
- 239000003292 glue Substances 0.000 claims description 27
- 235000016709 nutrition Nutrition 0.000 claims description 27
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 22
- 230000035764 nutrition Effects 0.000 claims description 21
- 229960003624 creatine Drugs 0.000 claims description 20
- 239000006046 creatine Substances 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 16
- LVRFTAZAXQPQHI-UHFFFAOYSA-N alpha-hydroxyisocaproic acid Natural products CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 230000003915 cell function Effects 0.000 claims description 14
- 230000006567 cellular energy metabolism Effects 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 14
- 210000000715 neuromuscular junction Anatomy 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 12
- 240000003183 Manihot esculenta Species 0.000 claims description 11
- 239000000419 plant extract Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 241000628997 Flos Species 0.000 claims description 10
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 10
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 10
- 229960004203 carnitine Drugs 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 235000005739 manihot Nutrition 0.000 claims description 10
- 235000013336 milk Nutrition 0.000 claims description 10
- 239000008267 milk Substances 0.000 claims description 10
- 210000004080 milk Anatomy 0.000 claims description 10
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 claims description 10
- 235000021283 resveratrol Nutrition 0.000 claims description 10
- 229940016667 resveratrol Drugs 0.000 claims description 10
- 230000008719 thickening Effects 0.000 claims description 10
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 9
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 9
- 244000005700 microbiome Species 0.000 claims description 9
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- -1 konjacmannan Substances 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 238000005491 wire drawing Methods 0.000 claims description 8
- 229920002907 Guar gum Polymers 0.000 claims description 7
- 229930003316 Vitamin D Natural products 0.000 claims description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 7
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 7
- 235000010417 guar gum Nutrition 0.000 claims description 7
- 239000000665 guar gum Substances 0.000 claims description 7
- 229960002154 guar gum Drugs 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 7
- 235000010491 tara gum Nutrition 0.000 claims description 7
- 239000000213 tara gum Substances 0.000 claims description 7
- 235000019166 vitamin D Nutrition 0.000 claims description 7
- 239000011710 vitamin D Substances 0.000 claims description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 7
- 229940046008 vitamin d Drugs 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- 241000195493 Cryptophyta Species 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 229960002173 citrulline Drugs 0.000 claims description 6
- 235000013477 citrulline Nutrition 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- 235000012054 meals Nutrition 0.000 claims description 6
- 229920001277 pectin Polymers 0.000 claims description 6
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 claims description 5
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 5
- 229920000161 Locust bean gum Polymers 0.000 claims description 5
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 5
- 229960003121 arginine Drugs 0.000 claims description 5
- 229960001231 choline Drugs 0.000 claims description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
- 229960002743 glutamine Drugs 0.000 claims description 5
- 150000002614 leucines Chemical class 0.000 claims description 5
- 235000019136 lipoic acid Nutrition 0.000 claims description 5
- 235000010420 locust bean gum Nutrition 0.000 claims description 5
- 239000000711 locust bean gum Substances 0.000 claims description 5
- 235000010987 pectin Nutrition 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 229960002663 thioctic acid Drugs 0.000 claims description 5
- 244000208874 Althaea officinalis Species 0.000 claims description 4
- 235000006576 Althaea officinalis Nutrition 0.000 claims description 4
- 241000416162 Astragalus gummifer Species 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 239000001884 Cassia gum Substances 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 244000239204 Plantago lanceolata Species 0.000 claims description 4
- 235000010503 Plantago lanceolata Nutrition 0.000 claims description 4
- 240000004584 Tamarindus indica Species 0.000 claims description 4
- 235000004298 Tamarindus indica Nutrition 0.000 claims description 4
- 229920001615 Tragacanth Polymers 0.000 claims description 4
- 244000250129 Trigonella foenum graecum Species 0.000 claims description 4
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims description 4
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 235000019318 cassia gum Nutrition 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 235000020235 chia seed Nutrition 0.000 claims description 4
- 235000019314 gum ghatti Nutrition 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 229940025902 konjac mannan Drugs 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010487 tragacanth Nutrition 0.000 claims description 4
- 239000000196 tragacanth Substances 0.000 claims description 4
- 229940116362 tragacanth Drugs 0.000 claims description 4
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 4
- 229920001222 biopolymer Polymers 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 201000010099 disease Diseases 0.000 description 22
- 235000021056 liquid food Nutrition 0.000 description 20
- 239000002245 particle Substances 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 206010035664 Pneumonia Diseases 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 208000002720 Malnutrition Diseases 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 210000003238 esophagus Anatomy 0.000 description 9
- 230000001071 malnutrition Effects 0.000 description 9
- 235000000824 malnutrition Nutrition 0.000 description 9
- 208000015380 nutritional deficiency disease Diseases 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 210000003300 oropharynx Anatomy 0.000 description 8
- 239000000835 fiber Substances 0.000 description 7
- 230000001771 impaired effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 230000018044 dehydration Effects 0.000 description 6
- 238000006297 dehydration reaction Methods 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 229920000591 gum Polymers 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 241000167880 Hirundinidae Species 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000004554 glutamine Nutrition 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000605909 Fusobacterium Species 0.000 description 3
- 229920002148 Gellan gum Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 239000004368 Modified starch Substances 0.000 description 3
- 206010030216 Oesophagitis Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 229940071162 caseinate Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000006881 esophagitis Diseases 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 235000010492 gellan gum Nutrition 0.000 description 3
- 239000000216 gellan gum Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 208000018360 neuromuscular disease Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 235000011649 selenium Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 241000193798 Aerococcus Species 0.000 description 2
- 206010002027 Amyotrophy Diseases 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- 230000007366 host health Effects 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 208000025644 recurrent pneumonia Diseases 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000019722 synbiotics Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 235000010930 zeaxanthin Nutrition 0.000 description 2
- 229940043269 zeaxanthin Drugs 0.000 description 2
- 239000001775 zeaxanthin Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- GTBJRWFFEQJCHN-REOHCLBHSA-N (2s)-3-hydroxy-2-(hydroxyamino)propanoic acid Chemical compound OC[C@H](NO)C(O)=O GTBJRWFFEQJCHN-REOHCLBHSA-N 0.000 description 1
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 208000006274 Brain Stem Neoplasms Diseases 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 241001310323 Cetraria Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 description 1
- 241000235035 Debaryomyces Species 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 1
- 208000032974 Gagging Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000037171 Hypercorticoidism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000019468 Iatrogenic Disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 208000029001 Mediastinal disease Diseases 0.000 description 1
- 241001468189 Melissococcus Species 0.000 description 1
- 208000026680 Metabolic Brain disease Diseases 0.000 description 1
- 206010062190 Metabolic encephalopathy Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- CNIUEVQJABPUIJ-QMMMGPOBSA-N N-hydroxytyrosine Chemical compound ON[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNIUEVQJABPUIJ-QMMMGPOBSA-N 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010052181 Oculopharyngeal dystrophy Diseases 0.000 description 1
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 1
- 241000202223 Oenococcus Species 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 208000007519 Plummer-Vinson syndrome Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001489223 Saccharomycodes Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040664 Sideropenic dysphagia Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000202221 Weissella Species 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FZHXIRIBWMQPQF-SLPGGIOYSA-N aldehydo-D-glucosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO FZHXIRIBWMQPQF-SLPGGIOYSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000151 anti-reflux effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ZMWZGZSARWJATP-UHFFFAOYSA-N divicine Chemical compound NC1=NC(N)=C(O)C(O)=N1 ZMWZGZSARWJATP-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 208000018066 neoplasm of oropharynx Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000007632 sclerotherapy Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical group O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000000152 swallowing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pediatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及包含至少一种食品级生物聚合物的水性溶液和至少一种生物活性化合物的稀薄内聚性液体食团,所述稀薄内聚性液体食团用于促进吞咽困难患者更安全地吞咽食团的用途,以及制备所述食团的方法。
Description
技术领域
本发明涉及包含至少一种食品级生物聚合物的水性溶液和至少一种生物活性化合物的稀薄内聚性液体食团(bolus),所述生物活性化合物为例如合成代谢化合物、抗分解代谢化合物、细胞功能或神经肌肉接点刺激化合物和细胞能量代谢刺激化合物。本发明还涉及所述稀薄内聚性液体食团用于促进吞咽困难的患者更安全地吞咽食物食团的用途,以及制备该食团的方法。
背景技术
吞咽困难(Dysphagia)是用于在吞咽中有困难的症状的医学术语。流行病学研究估计在50岁以上的个体中发病率为16%至22%。
食道吞咽困难影响所有年龄的大量个体,但通常可用药物治疗,并被认为是不太严重的吞咽困难形式。食道吞咽困难往往是粘膜疾病、纵隔疾病或神经肌肉疾病的后果。粘膜(内在的)疾病通过与各种病症(例如胃食道反流疾病、食道环和食道蹼[例如,缺铁性吞咽困难或普鲁默-文森(Plummer-Vinson)综合征]继发的消化道狭窄、食道肿瘤、化学损伤[例如,摄入腐蚀性物质、药片致食道炎、脉管曲张的硬化疗法]、辐射损伤、传染性食道炎和嗜酸细胞性食道炎)相关的炎症、纤维化或肿瘤形成而使管腔变窄。纵隔(外在的)疾病通过直接侵入或通过与各种病症(肿瘤[例如,肺癌、淋巴瘤]、感染[例如,肺结核、组织胞浆菌病]和心血管病症[心房扩张和血管压迫])相关的淋巴结肿大而阻塞食道。神经肌肉疾病可影响食道平滑肌及其神经支配,从而干扰蠕动或下食道括约肌松弛或者同时存在这两种情况,通常与各种病症(弛缓不能[自发性的和与查加斯(Chagas)病相关的]、硬皮病、其他动力障碍、以及外科手术后果[即,在胃底折叠术和抗返流干预后])相关。具有管腔内异物的个体经历急性食道吞咽困难也是常见的。
另一方面,口咽性吞咽困难是非常严重的病症,通常无法用药物治疗。口咽性吞咽困难也影响所有年龄的个体,但在老龄个体中更普遍。在全世界范围,口咽性吞咽困难影响大约2200万年龄50岁以上的人。口咽性吞咽困难往往是急性事件如中风、脑损伤或者口腔癌或喉癌手术的后果。另外,放射疗法和化学疗法可使肌肉变弱并使与吞咽反射的生理和神经支配相关的神经退化。患有进行性神经肌肉疾病如帕金森病的个体在吞咽起始方面经历不断增加的困难也是常见的。口咽性吞咽困难的代表性病因包括那些相关的神经系统疾病(脑干肿瘤、头部创伤、中风、脑瘫、格林-巴利(Guillain-Barre)综合征、亨廷顿病、多发性硬化、脊髓灰质炎、脊髓灰质炎后综合征、迟发性运动障碍、代谢性脑病、肌萎缩性侧索硬化、帕金森病、痴呆)、传染性疾病(白喉、肉毒中毒、莱姆病、梅毒、粘膜炎[疱疹性、巨细胞病毒、念珠菌等])、自身免疫疾病(狼疮、硬皮病、舍格伦综合征(Sjogren’ssyndrome))、代谢性疾病(淀粉样变性、库欣综合征(cushing’ssyndrome)、甲状腺毒症、威尔逊氏病(Wilson’sdisease))、肌源性疾病(结缔组织疾病、皮肌炎、重症肌无力、肌强直性营养不良、眼咽营养不良、多肌炎、肉样瘤病、副肿瘤综合征、炎性肌病)、医源性疾病(药物副作用[例如,化学疗法、神经弛缓剂等]、外科手术后肌肉或神经源性的疾病、放射疗法、腐蚀性[药丸损伤,故意的])以及结构性疾病(环咽嵴、岑克尔氏憩室(Zenker’sdiverticulum)、颈蹼、口咽肿瘤、骨赘和骨骼异常、先天性疾病[腭裂、憩室、囊等])。
尽管吞咽困难对患者健康和保健费用具有重大的后果,但它通常不被确诊。具有较严重的吞咽困难的个体通常经历食物从嘴到胃的传送受到损害的感觉,这种感觉在吞咽后立即出现。在社区居住的个体中,所感觉到的症状可能促使患者去看医生。在住院的个体中,健康护理人员可能观察到症状或者聆听患者或其家庭成员的提示吞咽损害的谈话,并建议该患者由专科医生进行评估。由于一线从业人员对吞咽损害的总体意识不高,吞咽困难往往得不到诊断和治疗。然而,通过转到吞咽专科医生(例如语音语言病理学家),患者可得到临床评估并且吞咽困难可得到确诊。
吞咽困难的严重性可分为:(i)在安全吞咽食物和液体方面存在极小的(感知到的)困难,(ii)不能吞咽,但没有明显的误吸或窒息风险,和(iii)完全不能够吞咽。通常,不能够正常吞咽食物和液体可能是由于食物食团破碎成较小的碎块所致,这些碎块在吞咽过程期间可能进入气道或在口咽道和/或食道中留下不想要的残留物(例如误吸)。如果足够多的物质进入肺部,有可能患者会因积聚在肺部中的食物/液体而溺亡。即使是少量的被误吸的食物也可能导致支气管肺炎感染,而慢性误吸可能导致支气管扩张并且可能造成一些哮喘病例。
“静默性误吸”是老年人中的常见病症,是指因缺乏咽反射而误吸口咽内容物(如分泌物、食物或液体),而又不出现咳嗽、清喉咙或痛苦的情况。人们可通过自我限制饮食而弥补严重性较低的吞咽损害。衰老过程本身加上慢性疾病(如高血压或骨关节炎)会使老年人易于罹患可能得不到确诊和治疗的(临床症状不显的)吞咽困难,直到出现临床并发症如肺炎、脱水、营养不良(及相关并发症)。
肺炎是吞咽困难的一种常见临床后果。该病症往往需要急性住院治疗和急诊室就诊。在因误吸而发生肺炎的个体当中,由于当前的护理实践,“误吸性肺炎”的鉴别性诊断未必得到指出。根据美国近年来所做的保健利用情况调查,医院出院患者中有一百万人以上是肺炎患者,另外392000人属误吸性肺炎。主要诊断为一般性肺炎的个体平均住院时间为6天,住院治疗费用超过18000美元。由于误吸性肺炎的平均住院时间为8天,预期误吸性肺炎将带来更高的住院治疗费用。肺炎对于吞咽困难个体是威胁生命的,3个月内的死亡几率大约为50%(vanderSteen等人,2002年)。另外,如肺炎之类的严重损伤(insult)常常引发老年人健康状况的螺旋向下。损伤与摄食不足和缺乏活动相关,从而导致营养不良、机能衰退和虚弱。特定的干预(例如促进口腔健康、帮助恢复正常吞咽或补充吞咽安全的食团)将有益于具有复发性肺炎的风险(因为口咽内容物的误吸,包括静默性误吸)或者正经历复发性肺炎的人群。
与肺炎相似,脱水是吞咽困难的一种威胁生命的临床并发症。在患有神经退行性疾病(从而有可能患有吞咽损害)的住院个体中,脱水是常见的并发病。美国每年出院患者中,阿尔茨海默病、帕金森病和多发性硬化病症患者有近400000人,并且这些患者中多达15%遭受脱水。作为主要诊断的脱水与4天的平均住院时间和超过11000美元的住院治疗费用相关联。尽管如此,脱水是吞咽困难的一种可避免的临床并发症。
当吞咽损害导致害怕食物和液体噎塞、饮食速度下降和自我限制食物的选择时,会发生营养不良和相关并发症(例如,[尿道]感染、压力性溃疡、吞咽困难的严重性提高[需要更加受限制的食物选项、管饲和/或PEG放置,以及生活质量下降]、脱水、机能衰退和相关的后果[跌倒、痴呆、虚弱、活动性丧失和自主性丧失])。如果不加以矫正,营养摄入不足会加重吞咽困难,因为由于生理储备耗竭,有助于促进正常吞咽的肌肉变弱。营养不良与超过3倍的更大的感染风险相关联。在患有神经退行性疾病(因而很可能患有危害饮食充分性的慢性吞咽损害)的个体中,感染是常见的。美国每年出院患者中,阿尔茨海默病、帕金森病和多发性硬化病症患者有近400000人,并且这些患者中多达32%遭受尿道感染。
此外,营养不良对于患者的康复具有严重的影响。营养不良的患者住院时间更长,更有可能再次住院,并且住院治疗的费用更高。作为主要诊断的营养不良与8天的平均住院时间和近22000美元的住院治疗费用相关联。此外,营养不良导致非有意的体重减轻以及肌肉和力量的显著损失,从而最终损害活动性和自我照顾能力。随着机能的损失,看管人员的负担逐渐加重,从而迫使需要非正式看管人员,然后需要正式看管人员,再然后需要送交机构照料。但是,营养不良是吞咽困难的一种可避免的临床并发症。
在患有神经退行性病症(例如,阿尔兹海默病)的人群当中,在认知下降之前出现非有意的作为营养不良标志的体重减轻。另外,身体活动可有助于稳定认知健康。因此,重要的是确保患有神经退行性病症的人群有充足的营养,以帮助他们拥有力量和耐力来参与定期的治疗性锻炼和预防非有意的体重降低、肌肉萎缩、身体和认知机能损失、虚弱、痴呆以及看护人员负担不断增加。
吞咽困难的经济成本与以下方面有关:住院、再次住院、由于按绩效付费(payforperformance,“P4P”)而失去医疗补偿、感染、康复、工作时间的损失、就诊次数、药物的使用、劳动、照顾者的时间、照料儿童的费用、生活质量、对技术性护理的需求增加。吞咽困难和误吸会影响生活质量、发病率和死亡率。在受机构照料的具有吞咽困难和误吸的个体中,十二个月死亡率高(45%)。吞咽困难的诊断和早期管理的缺乏所致的临床后果的经济负担是显著的。
考虑到吞咽困难的普遍性、与其有关的可能并发症及其带来的花费用,仍需要提供用于治疗吞咽障碍的改进的方法,该方法可使标准的食团疗法的风险减至最低,促进食物食团的更安全吞咽并且预防或治疗遭受误吸的患者的吞咽困难的临床并发症。这种方法将改善众多且数量不断增加的遭受吞咽损害的人群的生活。特定的干预(例如为了促进口腔健康、帮助恢复正常吞咽或强化吞咽安全的食团)可以使人们能够用口饮食(而不是进行管饲和/或需要PEG放置)并且体验食物的与总体幸福感相关的心理社会方面,同时防止因缺乏足够的吞咽能力所致的潜在负面后果。改善吞咽困难患者的营养摄入也可以使这类患者能够安全且舒适地吞咽品种更多的食物和饮料产品,这可导致患者的总体上更健康的状况并防止进一步的与健康有关的衰退。
发明内容
本发明提供一种新型的、营养上强化的、吞咽安全的食团及其制备方法,从而满足这些需求。本发明的食团通过防止吞咽困难患者出现非有意的体重减轻和肌肉萎缩而有助于预防或治疗吞咽困难的临床并发症,并且因而有助于避免遭受吞咽障碍的患者出现机能衰退、身体和认知机能损失、虚弱并最终失去活动性。
因此,在第一方面,本发明涉及一种食团,该食团选自内聚性液体,所述内聚性液体具有(i)小于约400mPas的剪切粘度和(ii)由毛细管破裂拉伸流变测定(CapillaryBreakupExtensionalRheometry,CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间;所述食团包含:(1)至少一种食品级生物聚合物的水性溶液,所述食品级生物聚合物选自植物亲水胶体、微生物亲水胶体、动物亲水胶体、藻类亲水胶体,以及它们的任何组合;和(2)至少一种生物活性化合物,所述生物活性化合物选自以下物质:(a)合成代谢化合物;(b)抗分解代谢化合物;(c)细胞功能或神经肌肉接点刺激化合物;和(d)细胞能量代谢刺激化合物。
在本发明的第一方面的一个优选实施例中,(a)合成代谢化合物任选地选自亮氨酸、亮氨酸代谢物、α-羟基异己酸(HICA)、谷氨酰胺、精氨酸、瓜氨酸、肌酸、乳清、中链脂肪酸(MCFA),以及它们的组合;(b)抗分解代谢化合物任选地选自多不饱和脂肪酸(PUFA)、ω-3脂肪酸、肉碱、肌酸,以及它们的组合;(c)细胞功能或神经肌肉接点刺激化合物任选地选自胆碱、维生素D、肌酸、油酰乙醇胺(OEA)、白藜芦醇,以及它们的组合;(d)细胞能量代谢刺激化合物任选地选自抗氧化剂、辅酶Q10、肌酸、硫辛酸、肉碱、白藜芦醇、中链脂肪酸(MCFA),以及它们的组合。
在本发明的第一方面的又一个实施例中,该食团优选地选自稀薄内聚性液体,该稀薄内聚性液体具有(i)当在50s-1的剪切速率下测量时小于约50mPas、优选地5至45mPas、更优选地10至40mPas、最优选地20至30mPas的剪切粘度和(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间。
在本发明的第一方面的另一个实施例中,该食团优选地选自增稠内聚性液体,该增稠内聚性液体具有(i)当在50s-1的剪切速率下测量时超过约50mPas、优选地55至350mPas、更优选地60至200mPas、最优选地70至100mPas的剪切粘度和(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间。
还优选的是,在本发明的第一方面,在20℃的温度下,弛豫时间少于约2000ms,优选地约20ms至约1000ms,更优选地约50ms至约500ms,最优选地约100ms至约200ms。
在本发明的第一方面的又一个优选实施例中,该水性溶液包含浓度为至少0.01重量%至25重量%、优选地至少0.1重量%至15重量%、最优选地至少1重量%至10重量%的至少一种食品级生物聚合物。
在本发明的第一方面的再一个优选实施例中,该食品级生物聚合物是植物亲水胶体,该植物亲水胶体选自从植物提取的胶、得自植物的黏液,或它们的组合,其中任选地,该从植物提取的胶选自秋葵胶、魔芋甘露聚糖、他拉胶(taragum)、刺槐豆胶、瓜尔豆胶、胡芦巴胶、罗望子胶、肉桂胶、金合欢胶、茄替胶、果胶、改性纤维素(例如羧甲基纤维素、甲基纤维素、羟丙基甲基纤维素、羟丙基纤维素)、黄蓍胶、刺梧桐胶,或它们的任何组合,并且优选地,该从植物提取的胶是秋葵胶;和/或该得自植物的黏液选自猕猴桃黏液、仙人掌黏液、野鼠尾草籽黏液、洋车前草黏液、锦葵黏液、亚麻籽黏液、药蜀葵黏液、长叶车前草黏液、毛蕊花黏液、冰岛地衣(cetraria)黏液,或它们的组合,并且优选地,该得自植物的黏液是猕猴桃黏液和/或仙人掌黏液。
本发明的又一个优选的实施例涉及呈可服用形式的上述第一方面的食团,该可服用形式选自药物制剂、营养制剂、营养补充剂、膳食补充剂、功能食品、饮料产品、全餐(fullmeal)、营养上完全的配方,以及它们的组合。
本发明的再一个优选的实施例涉及在有需要的患者中用于治疗吞咽障碍、用于促进营养产品的安全吞咽和/或用于减轻营养产品吞咽期间的误吸风险的上述第一方面的食团。
本发明的一个特别优选的实施例涉及在遭受吞咽障碍的患者中用于支持、维持和/或改进力量和/肌肉健康的上述第一方面的食团。
在第二方面,本发明涉及一种用于制备选自内聚性液体的食团的方法,该方法包括以下步骤:(1)提供能够给该食团提供以下性质的至少一种食品级生物聚合物的水性溶液:(i)小于约400mPas的剪切粘度,和(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间;以及(2)向所述水性溶液加入至少一种选自以下物质的生物活性化合物:(a)合成代谢化合物;(b)抗分解代谢化合物;(c)细胞功能或神经肌肉接点刺激化合物;和(d)细胞能量代谢刺激化合物。
在本发明的第二方面的一个优选实施例中,(a)合成代谢化合物任选地选自亮氨酸、亮氨酸代谢物、α-羟基异己酸(HICA)、谷氨酰胺、精氨酸、瓜氨酸、肌酸、乳清、中链脂肪酸(MCFA),以及它们的组合;(b)抗分解代谢化合物任选地选自多不饱和脂肪酸(PUFA)、ω-3脂肪酸、肉碱、肌酸,以及它们的组合;(c)细胞功能或神经肌肉接点刺激化合物任选地选自胆碱、维生素D、肌酸、油酰乙醇胺(OEA)、白藜芦醇,以及它们的组合;(d)细胞能量代谢刺激化合物任选地选自抗氧化剂、辅酶Q10、肌酸、硫辛酸、肉碱、白藜芦醇、中链脂肪酸(MCFA),以及它们的组合。
在根据本发明的第二方面的方法的又一个实施例中,该食团优选地选自稀薄内聚性液体,其中在步骤(1)中,提供至少一种食品级生物聚合物的水性溶液,该水性溶液能够给该食团提供以下性质:(i)当在50s-1的剪切速率下测量时小于约50mPas、优选地5至45mPas、更优选地10至40mPas、最优选地20至30mPas的剪切粘度;和(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间。
在根据本发明的第二方面的方法的另一个实施例中,该食团优选地选自增稠内聚性液体,其中在步骤(1)中,提供至少一种食品级生物聚合物的水性溶液,该水性溶液能够给该食团提供以下性质:(i)当在50s-1的剪切速率下测量时超过约50mPas、优选地55至350mPas、更优选地60至200mPas、最优选地70至100mPas的剪切粘度;和(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间。
还优选的是,在本发明的第二方面,在20℃的温度下,弛豫时间少于约2000ms,优选地约20ms至约1000ms,更优选地约50ms至约500ms,最优选地约100ms至约200ms。
在本发明的第二方面的又一个优选实施例中,该水性溶液包含浓度为至少0.01重量%至25重量%、优选地至少0.1重量%至15重量%、最优选地至少1重量%至10重量%的该至少一种食品级生物聚合物。
在本发明的第二方面的再一个优选实施例中,该食品级生物聚合物是植物亲水胶体,该植物亲水胶体选自从植物提取的胶、得自植物的黏液,或它们的组合,其中任选地,该从植物提取的胶选自秋葵胶、魔芋甘露聚糖、他拉胶(taragum)、刺槐豆胶、瓜尔豆胶、胡芦巴胶、罗望子胶、肉桂胶、金合欢胶、茄替胶、果胶、改性纤维素(例如羧甲基纤维素、甲基纤维素、羟丙基甲基纤维素、羟丙基纤维素)、黄蓍胶、刺梧桐胶,或它们的任何组合,并且优选地,该从植物提取的胶是秋葵胶;和/或该得自植物的黏液选自猕猴桃黏液、仙人掌黏液、野鼠尾草籽黏液、洋车前草黏液、锦葵黏液、亚麻籽黏液、药蜀葵黏液、长叶车前草黏液、毛蕊花黏液、冰岛地衣黏液,或它们的组合,并且优选地,该得自植物的黏液是猕猴桃黏液和/或仙人掌黏液。
本发明的又一个优选的实施例涉及上述第二方面的方法,该方法还包括任选的步骤(3):稀释该食团,优选地水稀释比在2:1至50:1、更优选地3:1至20:1、最优选地5:1至10:1的范围内。
本发明的再一个优选的实施例涉及上述第二方面的方法,该方法还包括步骤(4):使该食团成为可服用形式,该可服用形式选自药物制剂、营养制剂、营养补充剂、膳食补充剂、功能食品、饮料产品、全餐、营养上完全的配方,以及它们的组合。
本发明的其他方面和实施例在下文中描述。
具体实施方式
本发明提供一种食团,该食团选自内聚性液体,所述内聚性液体具有(i)小于约400mPas的剪切粘度和(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间;该食团包含:(1)至少一种食品级生物聚合物的水性溶液,所述食品级生物聚合物选自植物亲水胶体、微生物亲水胶体、动物亲水胶体、藻类亲水胶体,以及它们的任何组合;和(2)至少一种生物活性化合物,所述生物活性化合物选自以下物质:(a)合成代谢化合物;(b)抗分解代谢化合物;(c)细胞功能或神经肌肉接点刺激化合物;和(d)细胞能量代谢刺激化合物。
食团
本文所用的术语“食团”指食物或饮料的可被患者吞咽的物理部分。所述食团可为固体、半固体或液体形式,并且可包含一种或多种营养物、食物或营养补充剂。优选地,该食团是液体。还优选的是,该食团具有患者可在一次吞咽活动中食用的体积。该液体食团优选的体积为1至50ml,优选地5至20ml,更优选地8至12ml。
本发明人已发现,给吞咽困难患者提供由于其拉伸粘度(不同于剪切粘度的效应)而具有提高的内聚性的食团,可大大减少这些患者吞咽的努力程度,以及减少残余物在口咽道和/或食道中积聚的风险。由此,具有增加的内聚性的食团通过使吞咽困难患者能够安全且舒适地吞咽品种更多的食物和饮料产品而给这些患者提供改进的营养摄入。这通过改进食团完整性从而给患者增加能够食用不同产品的信心来实现。通过改进的食物和水摄入实现的营养改善可导致患者的总体上更健康的状况并防止进一步的衰退。
因此,本发明的食团不仅在其剪切粘度方面进行了改进,而且在至少一种另外的流变特性(如其内聚性)方面进行了改进。
剪切粘度是一种通常测量的流变特性,其往往简称粘度,并且可通过本领域知道的任何方法测定。在本发明中,剪切粘度是在标准的研究级流变仪(安东帕公司(AntonPaar)MCR)中使用同心圆柱测定的。所述参数描述材料对所施加的剪切应力的反应。换句话说,剪切粘度是在横向或水平方向上施加在流体的表面上的“压力”(每单位面积的力)与流体中从上到下方向上的流体速度的变化(“速度梯度)之间的比率。
内聚性这个参数涉及液体的一部分当在流动中被伸展(拉伸、伸长)时,例如穿过缩颈、液滴在表面上脱湿(dewetting)或液体拉丝(liquidfilament)变薄时,保持在一起的能力。
在本发明的情形中,食团的弛豫时间作为其内聚性的量度是通过毛细管破裂拉伸流变测定(CaBER)实验测定的。毛细管破裂拉伸流变仪是采用拉伸应力的流变仪的一个例子。在本文所进行的测量食团的弛豫时间的CaBER实验期间,将一滴所述食团置于两个垂直对齐且平行的圆形金属表面之间,两个表面都具有6mm的直径。然后将两个金属表面在50ms(微秒)的时间区间里快速线性分离。这个伸展动作所形成的拉丝随后在界面张力的作用下变薄,并使用测量拉丝中间点的直径的激光片光定量跟踪该变薄过程。CaBER实验的弛豫时间是通过将变薄过程中拉丝直径的标准化自然对数对时间作图并确定这个曲线的线性部分的斜率(dln(D/D0)/dt)测定的,其中D是拉丝直径,D0是拉丝在时间0时的直径,t是拉丝变薄的时间。在这个情形中,弛豫时间于是定义为负三分之一(-1/3)乘以这个斜率的倒数,即-1/(3dln(D/D0)/dt)。
优选地,在CaBER实验期间,食团的细流直径随时间推移小于线性地下降(decreaselessthanlinearly),并且更优选地呈指数方式下降。
在一个优选的实施例中,该食团是稀薄内聚性液体,该稀薄内聚性液体具有(i)当在50s-1的剪切速率下测量时小于约50mPas、优选地5至45mPas、更优选地10至40mPas、最优选地20至30mPas的剪切粘度和(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间。
在另一个优选实施例中,该食团是增稠内聚性液体,该增稠内聚性液体具有(i)当在50s-1的剪切速率下测量时超过约50mPas、优选地55至350mPas、更优选地60至200mPas、最优选地70至100mPas的剪切粘度和(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间。
特别优选地,本发明的内聚性液体食团在20℃的温度下的弛豫时间小于约2000ms,优选地约20ms至约1000ms,更优选地约50ms至约500ms,最优选地约100ms至约200ms。
另一个实施例涉及稀释形式的内聚性液体食团,优选地水稀释比在2:1至50:1、更优选地3:1至20:1、最优选地5:1至10:1的范围内。举例说,2:1的稀释比意指1份营养产品稀释在2份水中。
另一个实施例涉及呈可服用形式的内聚性液体食团,该可服用形式可优选地选自药物制剂、营养制剂、营养补充剂、膳食补充剂、功能食品、饮料产品、全餐、营养上完全的配方,以及它们的组合。
生物聚合物
本发明的内聚性液体食团包含至少一种食品级生物聚合物的水性溶液,所述食品级生物聚合物选自植物亲水胶体、微生物亲水胶体、动物亲水胶体、藻类亲水胶体,以及它们的任何组合。
优选的是,这些生物聚合物以至少0.01重量%至25重量%、优选地至少0.1重量%至15重量%、最优选地至少1重量%至10重量%的浓度被包含在内聚性液体食团中。
合适的藻类亲水胶体优选地包括琼胶、卡拉胶、海藻酸盐,或它们的组合。微生物亲水胶体可选自黄原胶、结冷胶(gellangum)、卡德兰胶(curdlangum),或它们的组合。
合适的微生物亲水胶体优选地包括黄原胶、结冷胶、卡德兰胶(curdlangum),或它们的组合。
合适的动物亲水胶体优选地包括透明质酸、硫酸葡糖胺、硫酸软骨素、胶原、胶原肽,或它们的组合。
特别优选的是,该至少一种食品级生物聚合物选自植物亲水胶体。植物亲水胶体可优选地选自从植物提取的胶、得自植物的黏液,以及它们的组合。
本文所用的从植物提取的胶优选地包括以下任一者:秋葵胶、葡甘露聚糖(魔芋甘露聚糖)、半乳甘露聚糖(他拉胶、刺槐豆胶、瓜尔豆胶、胡芦巴胶)、罗望子胶、肉桂胶、阿拉伯胶(金合欢胶)、茄替胶、果胶、改性纤维素(例如羧甲基纤维素、甲基纤维素、羟丙基甲基纤维素、羟丙基纤维素)、黄蓍胶、刺梧桐胶,以及它们的组合。特别优选秋葵胶。
本文所用的得自植物的黏液优选地选自猕猴桃黏液、仙人掌黏液、野鼠尾草籽黏液、洋车前草黏液、锦葵黏液、亚麻籽黏液、药蜀葵黏液、长叶车前草黏液、毛蕊花黏液、冰岛地衣黏液,以及它们的组合。在一个优选的实施例中,该得自植物的黏液是猕猴桃黏液和/或仙人掌黏液。
在本发明的情形中,猕猴桃黏液优选地衍自猕猴桃的茎髓,其含有约20%的黏液,并且通常代表猕猴桃农业的植物废弃物。
此外,在这个情形中,胶和黏液优选地是食品级的,并且可在商业上从多个供应商获得。
作为另一种选择,上述胶和黏液可通过本领域已知的任何合适的提取方法获得。例如,可通过包括如下步骤的方法提取胶和黏液:将植物原料用其10倍重量的蒸馏水浸泡,并且保持过夜。获得粘稠的溶液,使其穿过有机棉布(muslincloth)。通过以约1:1的比率添加95重量%的乙醇,伴以连续搅拌,使胶或黏液沉淀。获得凝结的料团,随后将其在40至45℃的烘箱中干燥,通过使其穿过筛子进行粉末化,并在气密性容器中保藏。
在一个特别优选的实施例中,稀薄内聚性液体食团包含食品级生物聚合物,该食品级生物聚合物选自秋葵胶、仙人掌黏液和猕猴桃黏液,或它们的任何组合。
在另一个特别优选的实施例中,增稠内聚性液体食团包含至少一种选自秋葵胶、仙人掌黏液、猕猴桃黏液,以及它们的组合的食品级生物聚合物以及另外一种选自淀粉、改性淀粉、黄原胶、瓜尔豆胶、卡拉胶、他拉胶、刺槐豆胶、海藻酸盐和果胶的食品级生物聚合物。
生物活性化合物
本发明的内聚性液体食团还包含至少一种生物活性化合物,该生物活性化合物选自合成代谢化合物、抗分解代谢化合物、细胞功能或神经肌肉接点刺激化合物和细胞能量代谢刺激化合物。
合适的合成代谢化合物优选地包括亮氨酸、亮氨酸代谢物、α-羟基异己酸(HICA)、谷氨酰胺、精氨酸、瓜氨酸、肌酸、乳清、中链脂肪酸(MCFA),以及它们的组合。
合适的抗分解代谢化合物优选地包括多不饱和脂肪酸(PUFA)、ω-3脂肪酸、肉碱、肌酸,以及它们的组合。
合适的细胞功能或神经肌肉接点刺激化合物优选地包括胆碱、维生素D、肌酸、油酰乙醇胺(OEA)、白藜芦醇,以及它们的组合。
合适的细胞能量代谢刺激化合物优选地包括抗氧化剂、辅酶Q10、肌酸、硫辛酸、肉碱、白藜芦醇、中链脂肪酸(MCFA),以及它们的组合。
本文所用的术语“抗氧化剂”被理解为包括能抑制由反应性氧物质(ReactiveOxygenSpecies,“ROS”)及其他自由基和非自由基物质促进的氧化或反应的各种物质中的任何一种或多种,如β-胡萝卜素(维生素A前体)、维生素C、维生素E和硒。另外,抗氧化剂是能够减慢或防止其他分子的氧化的分子。抗氧化剂的非限制性例子包括类胡罗卜素、辅酶Q10(“CoQ10”)、黄酮类、枸杞谷胱甘肽、橘皮苷、乳枸杞(lactowolfberry)、木脂素、叶黄素、番茄红素、多酚类、硒、维生素A、维生素B1、维生素B6、维生素B12、维生素C、维生素D、维生素E、玉米黄素,或它们的组合。
此外,本文所用的中链脂肪酸(MCFA)被理解为包括任何种类的具有一条或多条含6至12个碳原子的脂族尾链(aliphatictail)的脂肪酸,包括中链甘油三酯。
此外,本文所用的多不饱和脂肪酸(PUFA)被理解为包括任何种类的具有超过一个碳-碳双键的脂肪酸。
此外,本文所用的ω-3脂肪酸被理解为包括α-亚麻酸(ALA)、二十二碳六烯酸(DHA)和二十碳五烯酸(EPA)等,以及它们的组合。
刚性粒子
在又一个实施例中,本发明的食团可包含刚性粒子在内聚性液体中的悬浮液,优选地其中刚性粒子具有100nm至1mm,优选地200nm至900nm、300nm至800nm、400nm至700nm或500nm至600nm的尺寸。还优选的是,这些刚性粒子以1至50体积%的量被包含在食团中,优选地以5至40体积%、10至30体积%或15至20体积%的量被包含在食团中。
而且,特别优选的是,刚性粒子具有细长的形状,这意味着它们具有大于1.0的纵横比。
在本发明的情形中,术语“刚性”意指粒子在吞咽期间遇到的力作用下不显示可测量的变形。
刚性粒子可由任何食品级材料构成,并且优选地选自蔗糖晶体、可可粒子、咖啡粒子、芥末粒子、微晶纤维素粒子、淀粉和改性淀粉颗粒、蛋白质粒子,以及它们的任何组合。
在本发明的情形中,粒子尺寸以平均当量粒子直径表示。在本发明的情形中,当量粒子直径指具有与该粒子体积相等的体积的球体的直径,这可通过本领域已知的任何合适的方法测定。优选地,当量粒子直径通过激光衍射测定,例如使用粒度分析仪(Mastersizer)测定。此外,在这个情形中,平均当量粒子直径基于平均数,这应理解为样品中所有粒子直径的算术平均值,通常以D[1,0]报告。
在本发明的情形中,体积%表示以悬浮液的总体积计,所述悬浮液中的所有刚性粒子作为一个整体的体积的百分数。
据发现,本发明的食团中的这类刚性粒子的存在能局部地增强拉伸流动,从而提高拉伸应力,导致所述产品的较高的表观拉伸粘度。
另外的可能成分
该食团还可包含高分子量蛋白质,所述高分子量蛋白质优选地选自衍自胶原的蛋白质如明胶、植物蛋白质如马铃薯、豌豆、羽扇豆蛋白质等,或者其他具有足够高的分子量(分子量=100kDa及以上)的蛋白质。
该食团还可包含膳食蛋白质源,包括但不限于动物蛋白质(如肉类蛋白质或蛋类蛋白质)、乳品蛋白质(如酪蛋白、酪蛋白酸盐(例如,所有形式的酪蛋白酸盐,包括酪蛋白酸钠、酪蛋白酸钙、酪蛋白酸钾)、酪蛋白水解物、乳清(例如,所有形式的乳清,包括浓缩乳清、分离乳清、脱矿物质乳清)、乳清水解物、浓缩乳蛋白和分离乳蛋白)、植物蛋白质(如大豆蛋白、小麦蛋白、稻米蛋白和豌豆蛋白),或它们的组合。在一个优选的实施例中,蛋白质源选自乳清、鸡肉、玉米、酪蛋白酸盐、小麦、亚麻、大豆、长豆角、豌豆,或它们的组合。
该食团还可包含碳水化合物源。任何合适的碳水化合物都可用于本发明的食团中,包括但不限于蔗糖、乳糖、葡萄糖、果糖、玉米糖浆固形物、麦芽糖糊精、改性淀粉、直链淀粉、木薯淀粉、玉米淀粉,或它们的组合。
该食团还可包含脂肪源。脂肪源可包括任何合适的脂肪或脂肪混合物。例如,脂肪源可包括但不限于植物脂肪(如橄榄油、玉米油、葵花籽油、油菜籽油、榛子油、大豆油、棕榈油、椰子油、卡诺拉油菜油、卵磷脂等)、动物脂肪(如乳脂肪),或它们的组合。
该食团还可包含一种或多种益生元。本文所用的“益生元”是一种食物,其选择性地促进有益细菌在肠道中的生长或抑制病原性细菌在肠道中的生长或粘附于肠道粘膜。它们不会在摄入它们的人的胃和/或肠上部中被失活或在胃肠道中被吸收,而是它们被胃肠微生物群和/或被益生菌发酵。益生元的非限制性例子包括金合欢胶、α-葡聚糖、阿拉伯半乳聚糖、β-葡聚糖、右旋糖酐、果寡糖、岩藻糖基乳糖、半乳寡糖、半乳甘露聚糖、龙胆寡糖、葡寡糖、瓜尔豆胶、菊粉、异麦芽寡糖、乳新四糖(lactoneotetraose)、乳蔗糖、乳酮糖、果聚糖、麦芽糖糊精、乳品寡糖(milkoligosaccharides)、部分水解的瓜尔豆胶、果胶寡糖、抗性淀粉、回生淀粉、唾液酸寡糖、唾液酰乳糖、大豆寡糖类、糖醇类、木寡糖、它们的水解物,或它们的组合。
该食团还可包含一种或多种益生菌。本文所用的益生微生物(下文称为“益生菌”)为食品级微生物(活的,包括半活的或弱化的,和/或非复制性的)、代谢物、微生物细胞制剂或微生物细胞成分,其当以足够量施用时能赋予宿主健康益处,更具体而言,其通过改善宿主肠内微生物平衡有益地影响宿主,从而导致宿主健康或幸福的效果。一般来讲,据信这些微生物抑制或影响病原性细菌在肠道中的生长和/或代谢。益生菌还可激活宿主的免疫功能。益生菌的非限制性例子包括气球菌属(Aerococcus)、曲霉属(Aspergillus)、拟杆菌属(Bacteroides)、双歧杆菌属(Bifidobacterium)、假丝酵母属(Candida)、梭菌属(Clostridium)、德巴利酵母属(Debaromyces)、肠球菌属(Enterococcus)、梭杆菌属(Fusobacterium)、乳杆菌属(Lactobacillus)、乳球菌属(Lactococcus)、明串球菌属(Leuconostoc)、蜜蜂球菌属(Melissococcus)、微球菌属(Micrococcus)、毛霉属(Mucor)、酒球菌属(Oenococcus)、片球菌属(Pediococcus)、青霉属(Penicillium)、消化链球菌属(Peptostrepococcus)、毕赤酵母属(Pichia)、丙酸杆菌属(Propionibacterium)、假链状菌属(Pseudocatenulatum)、根霉菌属(Rhizopus)、酵母菌属(Saccharomyces)、葡萄球菌属(Staphylococcus)、链球菌属(Streptococcus)、球拟酵母属(Torulopsis)、魏斯氏菌属(Weissella),或它们的组合。
该食团可包含一种或多种另外的氨基酸。合适的氨基酸的非限制性例子包括丙氨酸、精氨酸、天冬酰胺、天冬氨酸、瓜氨酸、半胱氨酸、谷氨酸、谷氨酰胺、甘氨酸、组氨酸、羟脯氨酸、羟丝氨酸、羟酪氨酸、羟赖氨酸、异亮氨酸、亮氨酸、赖氨酸、甲硫氨酸、苯丙氨酸、脯氨酸、丝氨酸、牛磺酸、苏氨酸、色氨酸、酪氨酸、缬氨酸,或它们的组合。
该食团还可包含一种或多种合生素、ω-3脂肪酸源和/或植物营养素。本文所用的合生素是一种补充剂,其包含共同作用以改善肠道微生物群落的以上所限定的益生元和益生菌两者。ω-3脂肪酸的非限制性例子包括鱼油、磷虾、家禽、蛋类,或其它植物或坚果源,如亚麻子、核桃、杏仁、藻类、改良的植物等。植物营养素的非限制性例子包括槲皮素、姜黄素和柠檬苦素,以及它们的组合。
该食团还可包含一种或多种另外的抗氧化剂,包括类胡罗卜素、辅酶Q10(“CoQ10”)、黄酮类、枸杞谷胱甘肽、橘皮苷、乳枸杞(lactowolfberry)、木脂素、叶黄素、番茄红素、多酚类、硒、维生素A、维生素B1、维生素B6、维生素B12、维生素C、维生素D、维生素E、玉米黄素,或它们的组合。
该食团还可包含纤维或不同类型纤维的共混物。该纤维共混物可以含有可溶性和不溶性纤维的混合物。可溶性纤维可包括例如果寡糖、金合欢胶、菊糖等。不溶性纤维可包括例如豌豆外纤维。
该食团还可包含其他功能性成分,所述功能性成分包括壳聚糖和蛋白质聚集体。壳聚糖是由随机分布的β-(1-4)连接的D-葡糖胺(脱乙酰化单元)和N-乙酰基-D-葡糖胺(乙酰化单元)组成的直链多糖。壳聚糖具有天然抗细菌特性,能辅助药物递送,且已知能快速凝血,以及具有其他潜在的有益效果。蛋白质聚集体是受通常包埋在蛋白质内部的、暴露于溶剂的疏水表面之间的相互作用驱动的未折叠蛋白质(miss-foldedproteins)的聚结物。
本文所用的术语“蛋白质”、“肽”、“寡肽”或“多肽”被理解为指任何这样的组成,其包括单一氨基酸(单体)、两个或多个通过肽键连接在一起的氨基酸(二肽、三肽或多肽)、胶原、其前体、同系物、类似物、模拟物、盐、前药、代谢物或片段,,或它们的组合。为清楚起见,除非另有指定,否则任何上述术语可互换使用。应认识到,多肽(或肽或蛋白质或寡肽)通常包含20种氨基酸(一般称作20种天然存在的氨基酸)以外的氨基酸,并且许多氨基酸(包括末端氨基酸)可通过天然过程(如糖基化)和其他翻译后修饰或本领域众所周知的化学修饰技术在给定多肽中被修饰。可存在于本发明的多肽中的已知修饰包括但不限于乙酰化、酰化、ADP-核糖基化、酰胺化、黄酮类或血红素部分的共价连接、多核苷酸或多核苷酸衍生物的共价连接、脂质或脂质衍生物的共价连接、磷脂酰肌醇的共价连接、交联、环化、二硫键形成、去甲基化、共价交联形成、胱氨酸形成、焦谷氨酸形成、甲酰化、γ-羧化、糖化(glycation)、糖基化、糖基磷脂酰肌醇(“GPI”)膜锚定点形成、羟化、碘化、甲基化、肉豆蔻酰化、氧化、蛋白水解加工、磷酸化、异戊二烯化、外消旋化、硒酰化、硫酸化、tRNA介导的氨基酸添加到多肽(如精氨酰化和遍在蛋白化)。术语“蛋白质”还包括“人造蛋白质”,其指由肽的交替重复(alternatingrepeat)构成的线性或非线性的多肽。
用途
本发明的内聚性液体食团可优选地用于在有需要的患者中治疗吞咽障碍。
在又一个实施例中,所述食团尤其可在遭受吞咽障碍的患者中用于支持、维持和/或改进力量和/肌肉健康。
在本发明的情形中,术语“吞咽障碍”指与吞咽的困难和/或损害有关的任何种类的生理机能不良和/或障碍,以及其症状,其用医学术语称为吞咽困难,包括食道和口咽吞咽困难,以及误吸。
本文所用的术语“治疗”包括预防性的防止性治疗(防止和/或减慢目标病理状况或障碍的发展)和治愈性、医治性或疾病改善性治疗,包括治愈、减慢、减轻所诊断的病理状况或障碍的症状和/或使所诊断的病理状况或障碍的进展停止的医疗措施;以及对处于罹患疾病的风险或怀疑已经罹患疾病的患者以及生病中的或已诊断患有疾病或医学病症的患者的治疗。该术语不必然意味着受试者被治疗至完全康复为止。术语“治疗”也指在未患疾病但可能易于发展不健康状况的个体中进行的健康保持和/或促进。术语“治疗”也旨在包括一种或多种主要的预防性或医治性措施的增强。术语“治疗”还旨在包括疾病或病症的饮食管理或者为了疾病或病症的预防或防止而进行的饮食管理。
本文所用的术语“患者”被理解为包括接受或预期接受如本文所限定的治疗的动物如哺乳动物,更优选地是人。尽管术语“个体”和“患者”在本文中常常用于指人,但是本发明并不限于此。因此,术语“个体”和“患者”指患有可得益于治疗的医学病症或处于医学病症风险中的任何动物、哺乳动物或人。
在这个情形中,“哺乳动物”包括但不限于啮齿动物、水生哺乳动物、家养动物例如狗和猫、农场动物如绵羊、猪、牛和马,以及人。如果使用术语“哺乳动物”,预期它还适用于其他能够显示由哺乳动物所显示或预期显示的效果的动物。
在又一个实施例中,本发明的内聚性液体食团可用于促进营养产品的安全吞咽,和/或用于减轻营养产品吞咽期间的误吸风险。这些方法包括向有需要的患者给予包含本发明的内聚性液体食团的营养产品。
本文所用的术语“营养产品”包括营养制剂、营养补充剂、膳食补充剂、功能食品、饮料产品、全餐、营养上完全的配方,以及它们的组合。
方法
本发明另外提供一种用于制备食团的方法,所述食团选自内聚性液体,该方法包括以下步骤:(1)提供至少一种能够给该食团提供以下性质的食品级生物聚合物的水性溶液:(i)小于约400mPas的剪切粘度,和(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间;并且(2)向所述水性溶液加入至少一种生物活性化合物,所述生物活性化合物选自以下物质:(a)合成代谢化合物;(b)抗分解代谢化合物;(c)细胞功能或神经肌肉接点刺激化合物;和(d)细胞能量代谢刺激化合物。
在本发明的方法中,术语“食品级生物聚合物”“剪切粘度”、“弛豫时间”、“合成代谢化合物”、“抗分解代谢化合物”、“细胞功能或神经肌肉接点刺激化合物”和“细胞能量代谢刺激化合物”中的每一者优选地如上文所限定。最优选地,在本发明的方法中,选自内聚性液体的食团是根据本发明的内聚性液体食团。
在一个优选的实施例中,本发明方法包括如下任选的另外步骤:稀释该食团,优选地水稀释比在2:1至50:1、更优选地3:1至20:1、最优选地5:1至10:1的范围内。
在又一个优选的实施例中,本发明方法包括如下的另外步骤:使该食团成为可服用形式,该可服用形式选自药物制剂、营养制剂、营养补充剂、膳食补充剂、功能食品、饮料产品、全餐、营养上完全的配方,以及它们的组合。
套件(kit)
最后,本发明提供包括一个或多个包含内聚性液体食团的容器的套件,每个容器分别包含稀薄内聚性液体食团或增稠内聚性液体食团。优选地,稀薄内聚性液体食团和增稠内聚性液体食团的特征如上文所限定。
Claims (15)
1.一种食团,该食团选自内聚性液体,所述内聚性液体具有:
(i)小于约400mPas的剪切粘度,和
(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间;
所述食团包含:
(1)至少一种食品级生物聚合物的水性溶液,所述食品级生物聚合物选自植物亲水胶体、微生物亲水胶体、动物亲水胶体、藻类亲水胶体,以及它们的任何组合;
和
(2)至少一种生物活性化合物,所述生物活性化合物选自以下物质:
(a)合成代谢化合物;
(b)抗分解代谢化合物;
(c)细胞功能或神经肌肉接点刺激化合物;和
(d)细胞能量代谢刺激化合物。
2.根据权利要求1所述的食团,其中:
(a)所述合成代谢化合物任选地选自亮氨酸、亮氨酸代谢物、α-羟基异己酸(HICA)、谷氨酰胺、精氨酸、瓜氨酸、肌酸、乳清、中链脂肪酸(MCFA),以及它们的组合;
(b)所述抗分解代谢化合物任选地选自多不饱和脂肪酸(PUFA)、ω-3脂肪酸、肉碱、肌酸,以及它们的组合;
(c)所述细胞功能或神经肌肉接点刺激化合物任选地选自胆碱、维生素D、肌酸、油酰乙醇胺(OEA)、白藜芦醇,以及它们的组合;
(d)所述细胞能量代谢刺激化合物任选地选自抗氧化剂、辅酶Q10、肌酸、硫辛酸、肉碱、白藜芦醇、中链脂肪酸(MCFA),以及它们的组合。
3.根据权利要求1或2所述的食团,其中所述食团选自具有以下性质的稀薄内聚性液体:
(i)当在50s-1的剪切速率下测量时小于约50mPas、优选地5至45mPas、更优选地10至40mPas、最优选地20至30mPas的剪切粘度;
和
(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间。
4.根据权利要求1或2所述的食团,其中所述食团选自具有以下性质的增稠内聚性液体:
(i)当在50s-1的剪切速率下测量时超过约50mPas、优选地55至350mPas、更优选地60至200mPas、最优选地70至100mPas的剪切粘度;
和
(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间。
5.根据前述权利要求中任一项所述的食团,其中在20℃的温度下,所述弛豫时间小于约2000ms,优选地约20ms至约1000ms,更优选地约50ms至约500ms,最优选地约100ms至约200ms。
6.根据前述权利要求中任一项所述的食团,其中在CaBER实验期间,所述食团的拉丝直径随时间推移小于线性地下降,并且优选地呈指数方式下降。
7.根据前述权利要求中任一项所述的食团,其中所述水性溶液包含浓度为至少0.01重量%至25重量%、优选地至少0.1重量%至15重量%、最优选地至少1重量%至10重量%的所述至少一种食品级生物聚合物。
8.根据前述权利要求中任一项所述的食团,其中所述食品级生物聚合物是植物亲水胶体,所述植物亲水胶体选自从植物提取的胶、得自植物的黏液,或它们的组合,其中任选地,
所述从植物提取的胶选自秋葵胶、魔芋甘露聚糖、他拉胶、刺槐豆胶、瓜尔豆胶、胡芦巴胶、罗望子胶、肉桂胶、金合欢胶、茄替胶、果胶、改性纤维素(例如羧甲基纤维素、甲基纤维素、羟丙基甲基纤维素、羟丙基纤维素)、黄蓍胶、刺梧桐胶,或它们的任何组合,并且优选地,所述从植物提取的胶是秋葵胶;和/或
所述得自植物的黏液选自猕猴桃黏液、仙人掌黏液、野鼠尾草籽黏液、洋车前草黏液、锦葵黏液、亚麻籽黏液、药蜀葵黏液、长叶车前草黏液、毛蕊花黏液、冰岛地衣黏液,或它们的组合,并且优选地,所述得自植物的黏液是猕猴桃黏液和/或仙人掌黏液。
9.根据前述权利要求中任一项所述的食团,所述食团呈可服用形式,所述可服用形式选自药物制剂、营养制剂、营养补充剂、膳食补充剂、功能食品、饮料产品、全餐、营养上完全的配方,以及它们的组合。
10.根据前述权利要求中任一项所述的食团,所述食团在有需要的患者中用于治疗吞咽障碍、用于促进营养产品的安全吞咽和/或用于减轻营养产品吞咽期间的误吸风险。
11.根据权利要求1至9中任一项所述的食团,所述食团在遭受吞咽障碍的患者中用于支持、维持和/或改进力量和/肌肉健康。
12.一种用于制备食团的方法,该食团选自内聚性液体,所述方法包括以下步骤:
(1)提供至少一种食品级生物聚合物的水性溶液,所述水性溶液能够给所述食团提供以下性质:
(i)小于约400mPas的剪切粘度,和
(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间;
和
(2)向所述水性溶液加入至少一种生物活性化合物,所述生物活性化合物选自以下物质:
(a)合成代谢化合物;
(b)抗分解代谢化合物;
(c)细胞功能或神经肌肉接点刺激化合物;和
(d)细胞能量代谢刺激化合物。
13.根据权利要求12所述的方法,其中
(a)所述合成代谢化合物任选地选自亮氨酸、亮氨酸代谢物、α-羟基异己酸(HICA)、谷氨酰胺、精氨酸、瓜氨酸、肌酸、乳清、中链脂肪酸(MCFA),以及它们的组合;
(b)所述抗分解代谢化合物任选地选自多不饱和脂肪酸(PUFA)、ω-3脂肪酸、肉碱、肌酸,以及它们的组合;
(c)所述细胞功能或神经肌肉接点刺激化合物任选地选自胆碱、维生素D、肌酸、油酰乙醇胺(OEA)、白藜芦醇,以及它们的组合;和/或
(d)所述细胞能量代谢刺激化合物任选地选自抗氧化剂、辅酶Q10、肌酸、硫辛酸、肉碱、白藜芦醇、中链脂肪酸(MCFA),以及它们的组合。
14.根据权利要求12或13所述的方法,其中所述食团选自稀薄内聚性液体,并且其中在步骤(1)中提供至少一种食品级生物聚合物的水性溶液,所述水性溶液能够给所述食团提供以下性质:
(i)当在50s-1的剪切速率下测量时小于约50mPas、优选地5至45mPas、更优选地10至40mPas、最优选地20至30mPas的剪切粘度,和
(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间。
15.根据权利要求12或13所述的方法,其中所述食团选自增稠内聚性液体,并且其中在步骤(1)中提供至少一种食品级生物聚合物的水性溶液,所述水性溶液能够给所述食团提供以下性质:
(i)当在50s-1的剪切速率下测量时超过约50mPas、优选地55至350mPas、更优选地60至200mPas、最优选地70至100mPas的剪切粘度,和
(ii)由毛细管破裂拉伸流变测定(CaBER)实验在20℃的温度下测得超过10ms(毫秒)的弛豫时间。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13172153.2 | 2013-06-14 | ||
EP13172153 | 2013-06-14 | ||
PCT/EP2014/061592 WO2014198606A1 (en) | 2013-06-14 | 2014-06-04 | Cohesive liquid bolus comprising bioactives |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105283171A true CN105283171A (zh) | 2016-01-27 |
Family
ID=48613509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480032861.6A Pending CN105283171A (zh) | 2013-06-14 | 2014-06-04 | 包含生物活性物的内聚性液体食团 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20160129118A1 (zh) |
EP (1) | EP3007677A1 (zh) |
JP (1) | JP2016521738A (zh) |
CN (1) | CN105283171A (zh) |
AU (1) | AU2014280407A1 (zh) |
BR (1) | BR112015029966A2 (zh) |
CA (1) | CA2911098A1 (zh) |
WO (1) | WO2014198606A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113163829A (zh) * | 2018-12-13 | 2021-07-23 | 雀巢产品有限公司 | 配制用于稀释成营养产品以促进患有吞咽困难的个体安全吞咽的液体浓缩物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012117065A1 (en) * | 2011-03-01 | 2012-09-07 | Nestec S.A. | Extensional viscosity to promote safe swallowing of food boluses |
CN103037874A (zh) * | 2010-06-04 | 2013-04-10 | N·V·努特里奇亚 | 用于吞咽困难患者的预增稠致密液体营养组合物 |
CN104125779A (zh) * | 2011-12-15 | 2014-10-29 | 雀巢产品技术援助有限公司 | 在吞咽困难患者中促进安全吞咽的粘性稀薄液体 |
-
2014
- 2014-06-04 EP EP14733540.0A patent/EP3007677A1/en not_active Withdrawn
- 2014-06-04 WO PCT/EP2014/061592 patent/WO2014198606A1/en active Application Filing
- 2014-06-04 CN CN201480032861.6A patent/CN105283171A/zh active Pending
- 2014-06-04 US US14/897,293 patent/US20160129118A1/en not_active Abandoned
- 2014-06-04 JP JP2016518926A patent/JP2016521738A/ja not_active Withdrawn
- 2014-06-04 AU AU2014280407A patent/AU2014280407A1/en not_active Abandoned
- 2014-06-04 BR BR112015029966A patent/BR112015029966A2/pt not_active IP Right Cessation
- 2014-06-04 CA CA2911098A patent/CA2911098A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103037874A (zh) * | 2010-06-04 | 2013-04-10 | N·V·努特里奇亚 | 用于吞咽困难患者的预增稠致密液体营养组合物 |
WO2012117065A1 (en) * | 2011-03-01 | 2012-09-07 | Nestec S.A. | Extensional viscosity to promote safe swallowing of food boluses |
CN104125779A (zh) * | 2011-12-15 | 2014-10-29 | 雀巢产品技术援助有限公司 | 在吞咽困难患者中促进安全吞咽的粘性稀薄液体 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113163829A (zh) * | 2018-12-13 | 2021-07-23 | 雀巢产品有限公司 | 配制用于稀释成营养产品以促进患有吞咽困难的个体安全吞咽的液体浓缩物 |
Also Published As
Publication number | Publication date |
---|---|
BR112015029966A2 (pt) | 2017-07-25 |
US20160129118A1 (en) | 2016-05-12 |
CA2911098A1 (en) | 2014-12-18 |
WO2014198606A1 (en) | 2014-12-18 |
AU2014280407A1 (en) | 2015-11-05 |
EP3007677A1 (en) | 2016-04-20 |
JP2016521738A (ja) | 2016-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2909844T3 (es) | Líquidos poco densos cohesivos para estimular la deglución segura en pacientes disfágicos | |
US10806699B2 (en) | Method for treating a swallowing disorder | |
CN105283085A (zh) | 包含提供粘弹性的分子的粘性液体丸剂 | |
CN103402371A (zh) | 促进食物团块安全吞咽的拉伸粘度 | |
CN104114039A (zh) | 促进食物团块安全吞咽的拉伸粘度 | |
CN105263505A (zh) | 用于软骨破坏的组合物 | |
CN106535662A (zh) | 促进患有咽下困难的个体安全吞咽的营养产品 | |
CN105246499A (zh) | 用于软骨破坏的组合物 | |
TWI693898B (zh) | 稀釋型之營養組合物 | |
CN105283171A (zh) | 包含生物活性物的内聚性液体食团 | |
TWI725030B (zh) | 降低食品/飲料消化率/吸收率或減少消化液之方法及組合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160127 |
|
WD01 | Invention patent application deemed withdrawn after publication |